Vinge represents Altor in connection with its investment in H2 Green Steel. The investment has been carried out in connection with 1.5 billion euro investment round in H2 Green Steel. Investors participating in the capital raise included, in addition to Altor, inter alia AMF, GIC, Hitachi Energy, Kinnevik, Schaeffler, Andra AP-fonden, FAM, Hy24 and Just Climate.

H2 Green Steel was founded in 2020 with the ambition to accelerate the decarbonization of hard-to-abate industries. The company is starting with steel, which is one of the world’s largest carbon dioxide emitters, building a plant in Boden, northern Sweden. The plant will produce green steel, reducing CO2 emissions with up to 95 percent compared to traditional steelmaking. Groundwork has been in progress at the Boden site since the summer of 2022, and with this transaction, H2 Green Steel is taking a significant step closer to commencing operations by the end of 2025.

Vinge's team consisted mainly of Johan Larsson, Isabelle Wållgren, Robin Fagerström (M&A), Christoffer Nordin, Jolene Reimerson, Elis Allmark (Commercial Agreements), Johan Cederblad, Lina Österberg (Environment), Kristoffer Larson (Real Estate), Mathilda Persson (IT), Mia Falk, Julia Löfqvist (Compliance), Louise Brorsson Salomon, Helena Göransson, Kamyar Najmi (Banking and Finance), Axel Lennartsson (IP), Johan Wahlbom (Competition law), Daniel Wendelsson (Regulatory), Emy Rydén and Ottilia Pettersson (project assistants).

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025